HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), has announced signing a non-binding Letter of Intent (LOI) to acquire a premier West Coast Interventional Psychiatric Clinic. This acquisition is set to establish HOPE's model for a network of clinics across the country, providing advanced treatments for CNS disorders such as suicidal depression and PTSD.
Key points of the announcement include:
- The clinic's founder, a nationally recognized leader in advanced CNS disorder treatments, will join HOPE as Chief Medical Innovation Officer (CMIO).
- The acquisition is expected to be immediately accretive to revenue and EBITDA for both HOPE and NRx.
- The clinic will serve as a prototype for HOPE's network, offering treatments like Ketamine, Spravato, Transcranial Magnetic Stimulation (TMS), and talk therapy.
- Patients may also gain access to clinical trials of new treatment modalities through these clinics.
HOPE Therapeutics, Inc., una filiale di NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ha annunciato la firma di una Lettera di Intenti (LOI) non vincolante per acquisire una clinica psichiatrica interventistica di prim'ordine sulla Costa Ovest. Questa acquisizione mira a stabilire il modello di HOPE per una rete di cliniche in tutto il paese, fornendo trattamenti avanzati per disturbi del SNC come la depressione suicidaria e il PTSD.
I principali punti dell'annuncio includono:
- Il fondatore della clinica, un leader riconosciuto a livello nazionale nei trattamenti avanzati per i disturbi del SNC, entrerà in HOPE come Chief Medical Innovation Officer (CMIO).
- Ci si aspetta che l'acquisizione sia immediatamente accretiva ai ricavi e all'EBITDA sia per HOPE che per NRx.
- La clinica fungerà da prototipo per la rete di HOPE, offrendo trattamenti come Ketamina, Spravato, Stimolazione Magnetica Transcranica (TMS) e terapia conversazionale.
- I pazienti potrebbero anche avere accesso a studi clinici su nuove modalità di trattamento tramite queste cliniche.
HOPE Therapeutics, Inc., una subsidiaria de NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ha anunciado la firma de una Carta de Intención (LOI) no vinculante para adquirir una clínica psiquiátrica intervencionista de primer nivel en la Costa Oeste. Esta adquisición tiene como objetivo establecer el modelo de HOPE para una red de clínicas en todo el país, proporcionando tratamientos avanzados para trastornos del SNC como la depresión suicida y el PTSD.
Los puntos clave del anuncio incluyen:
- El fundador de la clínica, un líder reconocido a nivel nacional en tratamientos avanzados para trastornos del SNC, se unirá a HOPE como Director de Innovación Médica (CMIO).
- Se espera que la adquisición sea inmediatamente accretiva a los ingresos y EBITDA tanto para HOPE como para NRx.
- La clínica servirá como prototipo para la red de HOPE, ofreciendo tratamientos como Ketamina, Spravato, Estimulación Magnética Transcraneal (TMS) y terapia conversacional.
- Los pacientes también podrán acceder a ensayos clínicos de nuevas modalidades de tratamiento a través de estas clínicas.
HOPE Therapeutics, Inc.는 NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)의 자회사로, 프리미엄 웨스트 코스트 인터벤셔널 정신과 클리닉을 인수하기 위한 비구속 의향서(LOI)를 체결하였다고 발표했습니다. 이번 인수는 HOPE의 전국 클리닉 네트워크 모델을 확립하고 자살 우울증 및 PTSD와 같은 CNS 장애에 대한 선진 치료를 제공하는 것을 목표로 합니다.
발표의 주요 내용은 다음과 같습니다:
- 클리닉의 창립자는 CNS 장애 치료의 선도자로 인정받아 HOPE의 최고 의료 혁신 책임자(CMIO)로 합류할 것입니다.
- 이번 인수는 HOPE와 NRx 모두에게 즉각적으로 수익과 EBITDA에 긍정적인 영향을 미칠 것으로 예상됩니다.
- 클리닉은 HOPE의 네트워크를 위한 프로토타입 역할을 하며, 케타민, 스프라바토, 경두개 자기 자극(TMS) 및 상담 치료와 같은 치료법을 제공할 것입니다.
- 환자들은 이러한 클리닉을 통해 새로운 치료 방법에 대한 임상 시험에 접근할 수도 있습니다.
HOPE Therapeutics, Inc., une filiale de NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a annoncé la signature d'une Lettre d'Intention (LOI) non contraignante pour acquérir une clinique psychiatrique interventionnelle de premier plan sur la Côte Ouest. Cette acquisition vise à établir le modèle de HOPE pour un réseau de cliniques à travers le pays, fournissant des traitements avancés pour des troubles du SNC tels que la dépression suicidaire et le PTSD.
Les points clés de l'annonce comprennent :
- Le fondateur de la clinique, un leader reconnu au niveau national dans les traitements avancés pour les troubles du SNC, rejoindra HOPE en tant que Directeur de l'Innovation Médicale (CMIO).
- On s'attend à ce que l'acquisition soit immédiatement accretive au chiffre d'affaires et à l'EBITDA pour HOPE et NRx.
- La clinique servira de prototype pour le réseau de HOPE, offrant des traitements tels que la Kétamine, le Spravato, la Stimulation Magnétique Transcrânienne (TMS) et la thérapie verbale.
- Les patients pourraient également avoir accès à des essais cliniques de nouvelles modalités de traitement à travers ces cliniques.
HOPE Therapeutics, Inc., eine Tochtergesellschaft von NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), hat die Unterzeichnung eines unverbindlichen Letter of Intent (LOI) zur Übernahme einer führenden psychiatrischen Interventionsklinik an der Westküste bekannt gegeben. Diese Übernahme soll HOPEs Modell für ein Netzwerk von Kliniken im ganzen Land etablieren, das fortschrittliche Behandlungen für zentrale Nervensystemstörungen wie suizidale Depression und PTSD anbietet.
Die wichtigsten Punkte der Ankündigung umfassen:
- Der Gründer der Klinik, ein national anerkannter Führer in der Behandlung fortgeschrittener CNS-Störungen, wird als Chief Medical Innovation Officer (CMIO) zu HOPE stoßen.
- Es wird erwartet, dass die Übernahme sofort zu Umsatz und EBITDA sowohl für HOPE als auch für NRx beiträgt.
- Die Klinik wird als Prototyp für HOPEs Netzwerk dienen und Behandlungen wie Ketamin, Spravato, transkranielle Magnetstimulation (TMS) und Gesprächstherapie anbieten.
- Patienten könnten auch Zugang zu klinischen Studien neuer Behandlungsmethoden über diese Kliniken erhalten.
- Acquisition of a premier West Coast Interventional Psychiatric Clinic
- Nationally recognized clinic founder to become Chief Medical Innovation Officer of HOPE
- Acquisition expected to be immediately accretive to revenue and EBITDA for HOPE and NRx
- Establishment of a model for HOPE's clinic network across the country
- Expansion of treatment options for CNS disorders including Ketamine, Spravato, and TMS
- None.
Insights
The acquisition of a premier West Coast Interventional Psychiatric Clinic by HOPE Therapeutics represents a significant strategic move in the mental health treatment landscape. This deal brings several key advantages:
- Establishes a prototype for HOPE's planned network of Interventional Psychiatric Clinics
- Secures expertise of a nationally recognized leader in advanced CNS disorder treatments
- Provides immediate revenue and EBITDA growth for HOPE and NRx
- Expands treatment options including Ketamine, Spravatoâ, TMS and potential clinical trials
The acquisition aligns with the growing demand for innovative mental health treatments, particularly for conditions like suicidal depression and PTSD. By standardizing care across a network of clinics, HOPE aims to improve accessibility to cutting-edge therapies. However, investors should consider the execution risks associated with scaling this model and potential regulatory challenges in the evolving field of interventional psychiatry.
This acquisition presents a positive financial outlook for HOPE Therapeutics and its parent company, NRx Pharmaceuticals. Key financial implications include:
- Immediate accretion to revenue and EBITDA, suggesting a cash-flow positive acquisition
- Potential for scalable growth as the clinic model is replicated across a national network
- Diversification of revenue streams through multiple treatment modalities
- Possible increase in valuation multiples due to expansion into the high-growth mental health sector
For NRx, with a current market cap of
- Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric Clinics
- Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company's standard of care across the HOPE network
- Acquisition would be immediately accretive to revenue and EBITDA for HOPE and NRx
The clinic to be acquired will establish HOPE's model for clinics operating in the Company's network across the country, providing the highest standard of care to patients suffering from problems such as suicidal depression, PTSD and other CNS disorders. These treatments may include Ketamine, Spravatoâ, Transcranial Magnetic Stimulation (TMS), talk therapy and other treatment options. Additionally, patients may also have access to clinical trials of new treatment modalities through these clinics.
"This clinic is the ideal foundation for Hope's clinic network; the practice provides state-of-the-art treatment for patients dealing with many CNS disorders and has highly efficient operations; these aspects can serve as a model for future clinics entering our network," said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "Additionally, we look forward to working with the founder as our CMIO, as we establish HOPE as a model for clinics that aim to provide the latest standard of care treatments for CNS healthcare providers nationwide."
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a healthcare delivery company developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
CORPORATE CONTACTS:
Jeremy Feffer, LifeSci Advisors, Inc.
jfeffer@lifesciadvisors.com
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-CEO, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-signing-of-a-letter-of-intent-to-acquire-a-premier-west-coast-interventional-psychiatric-clinic-302266412.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the purpose of HOPE Therapeutics' acquisition of the West Coast Interventional Psychiatric Clinic?
How will the acquisition impact NRXP's financial performance?
What treatments will be offered at HOPE Therapeutics' clinics?
Who will become the Chief Medical Innovation Officer of HOPE Therapeutics?
